RetinaLyze®
An Artificial Intelligence tool for rapid retinal investigation, identifying diseases like:
- Glaucoma,
- Diabetic Retinopathy,
- Macular Degeneration
A powerful prevention tool and aid for medical professionals.
Precision and Speed: our AI technology analyzes images of the optic nerve, detecting signs of diseases with proven effectiveness
Without and With Retinalyze Pathology Detection
Detects eye pathologies in 3 quick steps:
With RetinaLyze®, it is possible to:
The algorithm classifies patients into two groups: those who need medical follow-up and those who do not. The ophthalmologists on the team can then focus on diagnosing and treating patients who really need their time. This way, RetinaLyze®️ reduces up to 60% of the manual workload.
RetinaLyze® provides instant results, through automated screening for signs of diabetic retinopathy, age-related macular degeneration, and glaucoma. There is also the possibility of integration with telemedicine platforms, allowing the sharing of images with doctors for diagnosis.
Security is very important to us. All communication is encrypted. An intermediary will not be able to view or edit images, results, or patient information. RetinaLyze® is registered with ANVISA and has CE marking. Data travels at the highest level of encryption currently available.
RetinaLyze® has been developed for easy use and learning by doctors and health professionals. The system can be easily adapted to meet the needs of a single clinic, a large network of ophthalmologists or hospitals, as well as for screening in prevention campaigns promoted by health professionals.
Global Impact: Case Studies
RetinaLyze® is backed by global scientific studies, demonstrating its accuracy and reliability in diagnosing eye diseases.
In Brazil, researchers from UNIFESP and UNICAMP validated its effectiveness in early identification of diabetic retinopathy, significantly contributing to the prevention of blindness.
Internationally, studies conducted in Europe and Asia confirm its utility in various clinical settings, establishing RetinaLyze® as an indispensable tool for ophthalmologists and health professionals.
O algoritmo classifica os pacientes em dois grupos: os que precisam de acompanhamento médico e os que não precisam. Os oftalmologistas da equipe podem então se concentrar em diagnosticar e tratar pacientes que realmente precisam de seu tempo. Desta forma, RetinaLyze® reduz até 60% da carga de trabalho manual.
RetinaLyze® provides instant results, through automated screening for signs of diabetic retinopathy, age-related macular degeneration, and glaucoma. There is also the possibility of integration with telemedicine platforms, allowing the sharing of images with doctors for diagnosis.
Security is very important to us. All communication is encrypted. An intermediary will not be able to view or edit images, results, or patient information. RetinaLyze® is registered with ANVISA and has CE marking. Data travels at the highest level of encryption currently available.
RetinaLyze® has been developed for easy use and learning by doctors and health professionals. The system can be easily adapted to meet the needs of a single clinic, a large network of ophthalmologists or hospitals, as well as for screening in prevention campaigns promoted by health professionals.
Global Impact: Case Studies
RetinaLyze® is backed by global scientific studies, demonstrating its accuracy and reliability in diagnosing eye diseases.
In Brazil, researchers from UNIFESP and UNICAMP validated its effectiveness in early identification of diabetic retinopathy, significantly contributing to the prevention of blindness.
Internationally, studies conducted in Europe and Asia confirm its utility in various clinical settings, establishing RetinaLyze® as an indispensable tool for ophthalmologists and health professionals.
Pathologies:
Glaucoma
The leading cause of preventable blindness worldwide.
About 2.5 millions people over 40 years old are affected in Brazil.
Diabetic Retinopathy,
One of the main causes of blindness in working-age people (16 – 64 years old).
About 90%s of cases could be prevented with early diagnosis and appropriate treatment.
AMD
A multifactorial disease, the progressive damage to the macula is the main cause of legal blindness in individuals over 50 years old.
Source: Mendez-Hernandez et. al 2016, Hernández, M.G. (2018)
